65,437 trials
Breast Cancer · Metastatic Breast Carcinoma · Invasive Breast Carcinoma
Primary: Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products — 9 participants
Prostate Cancer · Genetic Polymorphism
Primary: Progression Free Survival. — 6.0 Months
Insomnia · Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS). — -18.33; -23.45…
Osteoporosis
Primary: Percentage of Participants With New Vertebral Fractures Through Month 36 — 1.98; 2.14; 1.84; 3.13 Percentage of participants — p=0.22
Melanoma (Skin)
Primary: Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST — 3 participants
Osteoarthritis
Primary: Change in Knee Society Knee Score — 93.9; 93.7 scores on a scale
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Atrial Flutter · Ventricular Tachycardia
Primary: Navigation Performance — 1396 Successful locations
Venous Thrombosis · Deep Vein Thrombosis
Primary: Rate of Deep Vein Thrombosis — 14; 15; 9; 12 participants — p=0.785
Asthma
Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute
Heart Failure, Congestive
Primary: Rate of Heart Failure Related (HFR) Hospitalizations — 0.32; 0.44 HFR hospitalizations/patient/6 months — p=0.0002
Dyslipidemia · Hypercholesterolemia
Primary: Postprandial Incremental Area Under the Curve From 0-6 Hours (iAUC)[0-6] of Apolipoprotein B-48 (ApoB-48) — 63.4; 41.7 μg/mL x h — p=0.0078
Infected Toenails · Onychomycosis
Primary: Nail Bed Clearing
Dry Eye Syndromes
Primary: Percentage of Participants With Systemic Adverse Events (AEs) — 27.7; 8.7; 29.8; 27.1 percentage of participants
Human Immunodeficiency Virus Type 1
Primary: Number of Participants With Adverse Events — 195 Participants